Navigation Links
Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
Date:10/15/2007

PITTSBURGH, Oct. 15 /PRNewswire/ -- Knopp Neurosciences Inc. ("Knopp") announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation to KNS-760704 for the treatment of amyotrophic lateral sclerosis (ALS).

(Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO )

KNS-760704 is now completing Phase 1 studies to evaluate the safety, tolerability and pharmacokinetics of the compound in healthy human subjects. Knopp expects to initiate Phase 2 studies in ALS patients in the first quarter of 2008.

"Congress passed the Orphan Drug Act because it recognized that adequate drugs for many rare diseases have not been developed," said Michael Bozik, M.D., president and CEO of Knopp. "The designation of KNS-760704 as an orphan drug underscores the importance of developing effective treatments for patients with ALS."

About KNS-760704

KNS-760704 is an orally administered small molecule in clinical development by Knopp for the treatment of amyotrophic lateral sclerosis (ALS). The drug is an optical enantiomer of a selective, high affinity dopamine agonist marketed in other neurological indications. Both KNS-760704 and the marketed agonist demonstrate neuroprotective properties independent of dopamine receptor activity, but KNS-760704 exhibits greatly reduced dopamine receptor affinity. This makes it possible to clinically evaluate the potential neuroprotective activity of KNS-760704 over a broad dose range.

About ALS

Amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease, is a rapid, universally fatal neurodegenerative disorder characterized by progressive muscle weakness and wasting. ALS affects adults in the prime of life and creates a substantial burden for caregivers. U.S. prevalence is nearly 30,000 and the incidence is 1.2 per 100,000. Only a single drug has b
'/>"/>

SOURCE Knopp Neurosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
2. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
3. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
4. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
5. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
6. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
7. AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Point of Care Strep Tests Speed Treatment, Lower Costs
10. Rapid HIV Testing Increases Possibility of Treatment
11. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Pomerantz LLP has filed a class action ... EDAP ) and certain of its officers.  ... Southern District of New York , ... class consisting of all persons or entities who purchased ... 2014, inclusive (the "Class Period"). This class action seeks to ...
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3US CNS Disorders Drug Pipeline Insight 2014 2
... Tenn. , Jan. 20 Cumberland Pharmaceuticals Inc. ( ... ) Injection, an intravenous form of ibuprofen, to Haitian relief effort. ... for the treatment of pain and reduction of fever in ... continue to deteriorate, Caldolor is expected to help those suffering from ...
... , , LOS ANGELES , ... that it has joined forces with New Jersey -based ... create the nation,s first IVF insurance program. The Assisted Reproduction ... financial solutions for the ever-rising costs of In Vitro Fertilization ...
Cached Medicine Technology:Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort 2Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort 3New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nation's First In Vitro Fertilization Insurance Program 2New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nation's First In Vitro Fertilization Insurance Program 3
(Date:8/29/2014)... 2014 Healthpointe is proud to welcome ... Rodas will be practicing out of Healthpointe’s newest office ... of Healthpointe’s orthopedic team, Dr. Rodas is ... board-certified in occupational medicine. , Among Dr. Rodas’ ... Director of Raytheon, the world-class defense and aerospace company. ...
(Date:8/29/2014)... Healthpointe is pleased to provide ... students via Clinical Rotations. Physical Therapy ... Healthpointe providers and specialists throughout their daily clinical ... experience and learn professional preparation. , ... into several patient care techniques and expand their ...
(Date:8/29/2014)... August 29, 2014 Pursuing its deepest ... set to unveil a stunning new design that promises ... figures, the highly notable surrogacy platform has witnessed a ... over 13,000 visitors a month, the FindSurrogateMother.com community is ... toward one common goal — the precious gift of ...
(Date:8/29/2014)... trials based on administering antidepressants for acute and ... trials are needed to determine whether these drugs ... regular basis., Dr. Ian Gilron, a professor and ... of Anesthesiology, and his team of seven researchers ... of antidepressants for pain relief post-surgery would work ...
(Date:8/29/2014)... Grove Village, IL (PRWEB) August 29, 2014 ... innovator in hearing wellness solutions, is on its way ... 15-17 at the San Diego Convention Center to exhibit ... those who work in high-noise industrial environments. Etymotic’s safety ... the hottest wearable technology devices at the show. ...
Breaking Medicine News(10 mins):Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Antidepressants show potential for postoperative pain 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2
... and global IT giant Tata Consultancy Services (TCS) have ... a global drug development center in Mumbai. ... variety of services in clinical research, including clinical data ... ,"GSK has chosen to partner with TCS because of ...
... official figures.// ,Statistics for 2006 show ... which protects against measles, mumps and rubella, as against the national ... is an increase from the previous year, when the figure was ... 1988, but levels of uptake began to decline after 1998 when ...
... decided to crackdown on unethical doctors who accept gifts from ... entrance. ,This move follows the rocketing costs ... such tests. , According to the new law ... up to 5 years in jail, in terms of prosecution ...
... of persons infected with deadly viruses such as HIV and ... understand how. // , An independent inquiry is soon ... by almost 2000 hemophilia patients, via blood transfusions, in what ... of UK’s National Health Services. , The ...
... the “triple negative” type are destructive and lethal, and tend ... novel// study Published in the May 1, 2007 issue of ... occur commonly among women who are African American and Hispanic, ... socioeconomic status (SES). The study also showed that triple negative ...
... found that the most potent cholesterol-lowering drug is ... blood vessels that can lead to atherosclerosis. ... arteries compared to a placebo,” said John R.Crouse, ... at Wake Forest University School of Medicine. “The ...
Cached Medicine News:Health News:Scotland’s Parents Still a Little Wary of MMR Shot 2Health News:Inquiry into Past NHS Treatment Disaster 2Health News:'Triple Negative' Breast Cancers Seem to Affect the Young, Minority 2Health News:Cholesterol-lowering Drug Effective at Halting Early Atherosclerosis 2
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol...
The TVL-ADX lead is a thin, high-performing defibrillation lead that offers a true bipolar configuration designed for smarter sensing and low defibrillation threshold for greater patient safety margi...
... SPL defibrillator lead features a ... the flexibility and maneuverability of ... the physician who prefers a ... the SPL lead also promotes ...
Medicine Products: